Next Article in Journal
Pain in the Blood? Envisioning Mechanism-Based Diagnoses and Biomarkers in Clinical Pain Medicine
Next Article in Special Issue
Molecular Imaging of Tumors Using a Quantitative T1 Mapping Technique via Magnetic Resonance Imaging
Previous Article in Journal
Technologies for Clinical Diagnosis Using Expired Human Breath Analysis
Article Menu

Export Article

Open AccessReview
Diagnostics 2015, 5(1), 61-83;

Positron Emission Tomography in Breast Cancer

Clinical Area of Medical Imaging, Department of Nuclear Medicine, GIBI230, Polytechnic and University Hospital La Fe, Valencia 46026, Spain
Diagnostic Imaging, Sant Joan Despí Moisès Broggi Hospital, Sant Joan Despí, Barcelona 08970, Spain
Department of Nuclear Medicine, Provincial Hospital Consortium, Castellón de la Plana 12002, Spain
Department of Nuclear Medicine, General University Hospital-ERESA, Valencia 46018, Spain
Author to whom correspondence should be addressed.
Academic Editor: Andreas Kjaer
Received: 22 December 2014 / Revised: 3 March 2015 / Accepted: 4 March 2015 / Published: 16 March 2015
(This article belongs to the Special Issue NMR in Medicine)
Full-Text   |   PDF [1075 KB, uploaded 16 March 2015]   |  


Gradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of the advantages of this imaging modality versus CT, MRI, bone scan, mammography, or ultrasound, are based on its great diagnostic capacity since, according to the radiopharmaceutical used, it reflects metabolic changes that often occur before morphological changes and therefore allows us to stage at diagnosis. Moreover, another advantage of this technique is that it allows us to evaluate the whole body so it can be very useful for the detection of distant disease. With regard to breast cancer, FDG-PET/CT has proven to be important when recurrence is suspected or in the evaluation of treatment response. The technological advancement of PET equipment through the development of new detectors and equipment designed specifically for breast imaging, and the development of more specific radiopharmaceuticals for the study of the different biological processes of breast cancer, will allow progress not only in making the diagnosis of the disease at an early stage but also in enabling personalized therapy for patients with breast cancer. View Full-Text
Keywords: FDG-PET; PET/CT; PET/MRI; breast cancer; dedicated breast PET; non-FDG radiopharmaceuticals FDG-PET; PET/CT; PET/MRI; breast cancer; dedicated breast PET; non-FDG radiopharmaceuticals

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Vercher-Conejero, J.L.; Pelegrí-Martinez, L.; Lopez-Aznar, D.; Cózar-Santiago, M.P. Positron Emission Tomography in Breast Cancer. Diagnostics 2015, 5, 61-83.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top